Dr Samuel Hyde, working at Buxton in Derbyshire, would hardly have been harassed by concern for the adverse effects of interacting drugs. In his practice of rheumatology he may well have used the popular mixture containing aspirin and sodium bicarbonate. The second drug was added to correct the gastrointestinal side-effects of aspirin. Unfortunately, an additional and unexpected factor complicates this combination. Salicylates are more rapidly excreted in alkaline urine and it becomes impossible to achieve blood levels adequate to control inflammation. The ramifications of such a basic drug interaction are still not widely enough recognized. Levy et al. (1975) have recently shown that aluminium and magnesium hydroxide caused a 30-700% decrease in serum salicylate by a rise in urinary pH and increased renal clearance.
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Although there are many examples where drugs are combined so that one prevents sideeffects of the other, this paper considers the situation where the second drug is added to produce a hoped-for enhancement. Benorylatea tablet containing aspirin and paracetamol is a good example. The half-life of aspirin is prolonged through a metabolic effect in the liver and the patient has the advantage of needing only a twice-daily dose programme.
In treating patients with rheumatoid arthritis (RA) it is customary, if control is not achieved with aspirin, to add additional nonsteroidal anti-inflammatory drugs. Salicylates are maintained to gain time for the new drug to become effective and possibly to allow lower doses of the second drug to be used. In a group of 88 consecutive patients with RA attending my clinic 5 were on no medication at their last visit and 12 were on one anti-inflammatory drug (generally aspirin). The majority were on two or three drugs but 10 were on four and one, a 19-year-old female, was on five drugs. In this case, despite the use of such spectacular polypharmacy in the form of aspirin, indomethacin, ibuprofen, prednisolone and gold, symptoms and signs of inflammation were not controlled. Rather than adding to the effect perhaps some of these drugs were subtracting through an unexpected interaction. There is also good evidence that the number of drug defaulters increases when more than one drug is prescribed (Blackwell 1970) . Perhaps not all of these tablets were being swallowed by this patient.
In this group, 22 patients received additional drugs (even excluding the use of iron, vitamins and antacids) for other unrelated ailments. The majority were prescribed for hypertension and we note that phenylbutazone may reduce the effect of some hypotensives by causing sodium and fluid retention whilst frusemide may reduce the serum levels of concurrently administered indomethacin (Brooks, Bell, Lee, Rooney & Dick 1974) . Two patients received this combination. Two patients were on oral hypoglycamic agents despite the fact that aspirin and phenylbutazone are known to react with these drugs (Hartshorn 1971 , Birkett 1973 .
Of the 88 patients 85.5% were on salicylates, 50.5 % on indomethacin and 48 % on corticosteroids. The severity of disease in the group was the reason for the latter but the mean dose was low, the equivalent of 7.8 mg of prednisolone. Other drugs used were ibuprofen (26.5 %), gold (20.5%), hydroxychloroquine (7.2 %) and phenylbutazone (4.8 %).
Mechanisms ofDrug Interactions
Interactions may occur at any stage during the passage of a drug through the body from its absorption, through its transport in the blood and distribution in the tissues, to its metabolism and final excretion.
Absorption: Interactions are probably not very important to rheumatologists although antacids and indeed food can slow absorption, e.g. phenylbutazone (Graham 1973) . It has been' suggested by Jeremy & Towson (1970) that an interaction occurs between indomethacin and aspitin in the gastrointestinal tract (see below).
Transport: An important property of the antiinflammatory drugs is that most bind strongly to plasma proteins and in particular to albumin. Only the free drug which is in equilibrium with the bound drug is thought to possess biological activity (Brodie 1965). In Fig 1, drug A is strongly bouind to albumin and a smlnil amount is free in the plasma and in the tissues. A second drug (B) with similar binding properties is added and some displacement of A will occur. There is an increase in the free active form of the drug in plasma and in the tissues. Secondary events then come into play, e.g. there is increased excretion of the free drug and equilibrium may be established with a lower total drug concentration in the plasma. An example would be displacement of penicillin by salicylate leading to an increased amount of penicillin in the tissues of possible therapeutic benefit (Kunin 1964).
Recently published in vitro studies (Muirden et al. 1974 ) have shown protein-binding inter- actions between salicylates and ibuprofen, indomethacin, phenylbutazone and warfarin. Such experiments may not be directly applicable in vivo and in fact it is now fashionable to say that protein-binding interactions have been overemphasized. Well-defined examples of potentiation due to protein binding occur from salicylates or pyrazoles with warfarin, tolbutamide, chlorpropamide or phenytoin and from salicylates with methotrexate. penicillin and possibly fenoprofen.
It is known that the prescription of aspirin or phenylbutazone for a patient receiving warfarin prolongs the prothrombin time (Koch-Weser & Sellers 1971) . With aspirin there is the added effect on platelets (Mustard & Packham 1970) making the combination potentially lethal, particularly as aspirin so frequently causes gastric erosions. These interactions with anticoagulants are important as deep venous thrombosis in the calf is frequently misdiagnosed in RA. The same symptoms and signs are produced by rupture of a Baker's cyst.
The patient with active RA with a low serum albumin may well be unusually susceptible to changes induced by combinations of highly bound anti-inflammatory drugs. In most circumstances it is important to measure not just the total serum concentration but also the proportion of free drug. It may be that lower total levels produce the required clinical effect with fewer side-effects. Gugler et al. (1975) have studied the effect of phenytoin in patients with hypoalbuminmmia due to the nephrotic syndrome. Like -aspirin and phenylbutazone phenytoin is also strongly bound to albumin. Total blood levels could be 50% lower in patients than in controls whilst maintaining the same levels of free active drug. Both therapeutic effectiveness and toxicity are better related to the unbound drug than to total levels or even dosage.
Metabolism: Table 1 shows documented rather than theoretical examples of some relevance to rheumatologists (see also Birkett & Pond 1975).
Induction refers to stimulation of enzyme systems particularly in the liver. The drug is more rapidly metabolized and therapeutic effects decreasefor example the stimulation of steroid metabolism by phenytoin has been used to ameliorate the symptoms of Cushing's Syndrome (Werk et al. 1964 ). The reverse takes place with inhibition of enzyme systems when the effect of the drug is exaggerated. The diabetic on tolbutamide becomes more difficult to control when on phenylbutazone and there has been at least one death reported from the combination of 6-mercaptopurine with allopurinol and azathioprine with allopurinol because of increased bone marrow depression (Nies & Oates 1971) . Mu,h of the information available from animal studies is of limited value in predicting what will happen in man because of differences in metabolic pathways in various species.
Tissue or receptor effects: With the collaboration of Dr B Clarris, Dr R Fraser, Dr C Moran and Mr A Robertson we have attempted to show an effect of drugs, assuming that the synovial cell could be an important target in RA. To obtain these cells from our patients trypsin was injected into a swollen knee and 15 minutes later the joint was aspirated. Fortunately this has a beneficial effect even if only of a temporary nature and the procedure was performed at the time a steroid injection was indicated. Fig 2 shows the fleshy synovial cells aspirated post-trypsin from a rheumatoid joint. A monolayer culture was grown from such cells and, once established, drugs could be added to the medium. We have so far been able to demonstrate that aspirin is actively taken up by these cells. The method allows study of both normal and rheumatoid cells and the effect of drugs used singly or in combination. Fig 3 shows cells in culture growing happily in a medium containing aspirin 10 mg/ 100 ml.
Excretion interactions: Withdrawal of corticosteroids is often attempted under the cover of increased doses of other anti-inflammatory drugs such as aspirin. Our results agree with those of Klinenberg & Miller (1965) who demonstrated a rise in serum salicylate during steroid reduction despite a constant dose of aspirin. Such an event may result in unexpected salicylate toxicity and it probably results from a change in renal clearance of salicylate effected by the steroids. Conversely prescribing steroid for a patient already on aspirin may lead to lower salicylate blood levels.
Indomethecin shares the same tubular secretion mechanism as probenecid. Given together the excretion of indomethecin is slowed and higher blood levels are produced (Brooks, Bell, Sturrock, Famaey & Dick 1974) . There is considerable patient variation in the level of response but clinically an improvement in the measures of rheumatoid activity has been claimed. The Glas- gow group has also shown that frusemide significantly reduces the plasma level of indomethecin following concurrent administration of the two drugs orally (Brooks, Bell, Lee, Rooney & Dick 1974). The mechanism for this interaction is thought to include effects at both an absorptive and excretory level. Table 2 summarizes important 'inter-system' drug interactions.
Results ofDrug Combinations
The next problem to consider is whether two anti-inflammatory drugs given together will produce any obvious advantage over using one drug alone. Or even worsethere could be a reduction in efficiency of disease control which will be more difficult to pick up. Some interesting information has been collected using animal models. Swingle et al. (1970) showed that hydrocortisone inhibits carrageenan-induced foot cedema in rats and with the addition of either phenylbutazone, aspirin or indomethacin there is increased inhibition over each drug being used alone. However, with two of the nonsteroidal drugs used together there was no advantage.
In the second example Van Arman et al. (1973) use that rather curious model adjuvant arthritis in rats. Here if the animal is pretreated with low dosage aspirin the beneficial effects of hydroeortisone, prednisolone, phenylbutazone, indomethacin, flufenamic acid and cyclophosphamide are prevented. Further, the effect of indomethacin is antagonized by a strange group of drugs including aspirin, spironolactone, protriptyline and chlorpromazine. The aspirin-indomethacin interactions: I have mentioned that about 500% of our RA cases on salicylates were also on indomethacin. This important combination has been studied in two ways. The first is to measure indomethacin blood levels with or without salicylates. The literature is conflicting on this point. Jeremy & Towson (1970) showed a fall in serum indomethacin with salicylates and it was suggested that this was caused by a gastrointestinal absorption interaction. This was followed by a recommendation that the intake of aspirin and indomethacin should be separated by at least half an hour. As a suggestion this must rank as one of the more impractical a patient has to put up with. Champion et al. (1971) were unable to show that salicylate made any difference whilst Garnham et al. (1975) demonstrated an increased rate of indomethacin absorption leading to higher blood levels possibly influenced by the use of buffered aspirin. Recently, Gribnau et al. (1975) produced plasma concentration-time curves for indomethacin which certainly differed when aspirin was used concurrently. The area under the curve in each case 
Probenecid Salicylates, indomethacin, penicillin and cephalosporins Iron Antacids, tetracycline was the same so that there need be no overall change. in the drug's effect. In some cases the faster absorption and higher peak levels of indomethacin were with aspirin and with others the reverse was true. The results were consistent for the individuals tested but varied from case to case. Garnham et al. also noted this inter-subject variation. Our own results (Barraclough et al. 1975) indicate that it is possible to maintain indomethacin blood levels in the range recommended to produce a clinical effect in our patients despite concurrent administration of aspirin. So far as blood levels are concerned we take the view that the aspirin-indomethacin interaction is a minor one.
The other approach is to study the indices of rheumatoid activity in a group of patients with combined treatment or with one drug alone together with a placebo. Brooks et al. (1975) used indomethacin and aspirin alone and then together in a group of 20 RA patients. They showed no difference in clinical effect apart from an increase in side-effects when the two dru'gs were given concurrently. Dr Barbara Ansell (unpublished) has done a pilot study using indomethacin suppositories in addition to aspirin. With doses of 50 and 100 mg there was some added improvement in morning stiffness but not with any other parameters studied.
One problem in such studies is whether our methods of clinical assessment are sensitive enough to show up anything less than marked changes in disease activity. I believe we are very much in the dark about many potential interactions because our monitoring methods are so crude.
Therapy ofRheumatoid Arthritis It seems to me useful to divide the drugs we use into three groups (Fig 4) :
(1) Nonsteroidal drugs including salicylates which act within hours to suppress inflammation. From the still limited evidence available it is doubtful whether combinations which include two or more members of this group are a useful form of polypharmacy. Combinations of indo-methacin and aspirin remain popular, and a large dose of the former given at night to reduce morning stiffness is considered beneficial. It is better to use full doses of one drug rather than lower doses of many. With some of the newer drugs the dosage is still rather arbitrary and this adds to the problem.
(2) Drugs, including gold, which appear to act in a different and probably more profound way on the rheumatoid process. Their therapeutic effects do not develop for several weeks and their optimal effects are delayed for three months. Obviously the patient will need a member of the first group whilst awaiting the benefi of, say, gold. Again there seems little point in using more than one member of this group. In fact penicillamine would chelate the gold as another example of a not unexpected drug interaction. Immunosuppressives (3) and most of the other drugs listed are used for their steroid-sparing properties.
Hopefully, we would see as a maximum in a patient who was already being treated with steroids, one member of each group used to control the disease. In an ideal situation this is then followed by steroid reduction and ultimately the aim is to have the patient controlled on, say, maintenance gold alone.
Summary
The use of multiple drugs in treating rheumatoid arthritis is based on the assumption that their effects are additive. Sometimes the results are unexpected or the added drug may confer no additional benefit to the patient whilst leaving him more liable to undesirable side-effects.
Some form of polypharmacy may be necessitated by the different pharmacological properties of our drugs. Certain drugs have been judged on their steroid-sparing effects allowing lower doses to be used and thereby reducing the toxicity of corticosteroids.
It is likely that some potential areas of danger from interacting drugs have been over-empha- sized, being based on speculative rather than real data or purely on animal experiments using nonclinical doses.
The patient with active RA with a low serum albumin would be unusually susceptible to changes induced by combinations of strongly bound anti-inflammatory drugs. He would also be highly susceptible to side-effects, as has been shown with prednisone. Side-effects here are doubled when the patient's serum albumin is below 2.5 g/lOO ml (Lewis etal. 1971 ).
I believe we should continue to ask ourselves whether by subtracting one or more drugs from the patient's cocktail we may not produce a most welcome benefit for both patient and doctor and, I suppose we could even add, the hard-pressed tax payer.
